Infant respiratory distress syndrome

Last updated
Infant respiratory distress syndrome
Other namesNeonatal respiratory distress syndrome [1]
X-ray of infant respiratory distress syndrome (IRDS).png
Chest X-ray of a case of IRDS, with fine granular opacities, air bronchograms and bell-shaped thorax
Specialty Pediatrics, obstetrics   OOjs UI icon edit-ltr-progressive.svg

Infant respiratory distress syndrome (IRDS), also called respiratory distress syndrome of newborn, or increasingly surfactant deficiency disorder (SDD), [2] and previously called hyaline membrane disease (HMD), is a syndrome in premature infants caused by developmental insufficiency of pulmonary surfactant production and structural immaturity in the lungs. It can also be a consequence of neonatal infection and can result from a genetic problem with the production of surfactant-associated proteins. [3] [4]

Contents

IRDS affects about 1% of newborns and is the leading cause of morbidity and mortality in preterm infants. [5] Data have shown the choice of elective caesarean sections to strikingly increase the incidence of respiratory distress in term infants; dating back to 1995, the UK first documented 2,000 annual caesarean section births requiring neonatal admission for respiratory distress. [6] The incidence decreases with advancing gestational age, from about 50% in babies born at 26–28 weeks to about 25% at 30–31 weeks. The syndrome is more frequent in males, Caucasians, infants of diabetic mothers and the second-born of premature twins. [7]

IRDS is distinct from pulmonary hypoplasia, another leading cause of neonatal death that involves respiratory distress.[ citation needed ]

The European Consensus Guidelines on the Management of Respiratory Distress Syndrome highlight new possibilities for early detection, and therefore treatment of IRDS. [8] The guidelines mention an easy to use rapid point-of-care predictive test that is now available [9] and how lung ultrasound, with appropriate training, expertise and equipment, may offer an alternative way of diagnosing IRDS early. [10]

Signs and symptoms

IRDS begins shortly after birth and is manifested by fast breathing (more than 60 breaths per minute), a fast heart rate, chest wall retractions (recession), expiratory grunting, nasal flaring, and blue discoloration of the skin during breathing efforts.[ citation needed ]

As the disease progresses, the baby may develop ventilatory failure (rising carbon dioxide concentrations in the blood) and prolonged cessations of breathing ("apnea"). Whether treated or not, the clinical course for the acute disease lasts about two to three days. During the first day, the child worsens and requires more support. During the second day, the baby may be remarkably stable on adequate support and resolution is noted during the third day, heralded by a prompt diuresis. Despite huge advances in care, IRDS remains the most common single cause of death in the first month of life in the developed world. Complications include metabolic disorders (acidosis, low blood sugar), patent ductus arteriosus, low blood pressure, chronic lung changes and bleeding in the brain. The syndrome is frequently complicated by prematurity and its additional effect on other organ functions. [11]

Acute respiratory distress syndrome (ARDS) has some similarities to IRDS. Transient tachypnea of the newborn presents with respiratory distress syndrome in the Term child. [12]

Histopathology

The characteristic histopathology seen in babies who die from RDS was the source of the name "hyaline membrane disease". Waxlike layers of hyaline membrane line the collapsed alveoli of the lung. In addition, the lungs show bleeding, overdistention of airways, and damage to the lining cells.[ citation needed ]

Pathophysiology

The lungs of infants with respiratory distress syndrome are developmentally deficient in a material called surfactant, which helps prevent the collapse of the terminal air spaces (the future site of alveolar development) throughout the normal cycle of inhalation and exhalation. This deficiency of surfactant is related to inhibition from the insulin that is produced in the newborn, especially those of diabetic mothers. [13]

Pulmonary surfactant is a complex system of lipids, proteins and glycoproteins that is produced in specialized lung cells called Type II cells or Type II pneumocytes. The surfactant is packaged by the cell in structures called lamellar bodies, and extruded into the air spaces. The lamellar bodies then unfold into a complex lining of the air space. This layer reduces the surface tension of the fluid that lines the alveolar air space. Surface tension is responsible for approximately 2/3 of the inward elastic recoil forces. In the same way that a bubble will contract to give the smallest surface area for a given volume, so the air/water interface means that the liquid surface will tend toward being as small as possible, thereby causing the air space to contract. By reducing surface tension, surfactant prevents the air spaces from completely collapsing on exhalation. In addition, the decreased surface tension allows reopening of the air space with a lower amount of force. Therefore, without adequate amounts of surfactant, the air spaces collapse and are very difficult to expand.[ citation needed ]

Microscopically, a pulmonary surfactant-deficient lung is characterized by collapsed air spaces alternating with hyperexpanded areas, vascular congestion, and, in time, hyaline membranes. Hyaline membranes are composed of fibrin, cellular debris, red blood cells, rare neutrophils and macrophages. They appear as an eosinophilic, amorphous material, lining or filling the air spaces and blocking gas exchange. As a result, blood passing through the lungs is unable to pick up oxygen and unload carbon dioxide. Blood oxygen levels fall and carbon dioxide rises, resulting in rising blood acid levels and hypoxia. Structural immaturity, as manifested by a decreased number of gas exchange units and thicker walls, also contributes to the disease process. Therapeutic oxygen and positive-pressure ventilation, while potentially life-saving, can damage the lung.[ citation needed ]

Traditional diagnostic approach

The diagnosis is made by the clinical picture and the chest X-ray, which demonstrates decreased lung volumes (bell-shaped chest), absence of the thymus (after about six hours), a small (0.5–1 mm), discrete, uniform infiltrate (sometimes described as a "ground glass" appearance or "diffuse airspace and interstitial opacities") that involves all lobes of the lung and air-bronchograms (i.e. the infiltrate will outline the larger airways passages, which remain air-filled). In severe cases, this becomes exaggerated until the cardiac borders become indiscernible (a 'white-out' appearance).[ citation needed ]

Point-of-care lung maturity test

To improve clinical outcomes very early treatment with surfactant is necessary. [14] However, only about half of infants with a gestational age (GA) below 30 weeks need surfactant treatment [15] [16] and prophylactic surfactant treatment increases the combined mortality and incidence of Bronchopulmonary Dysplasia (BPD) contrary to selective rescue surfactant treatment. [17] Therefore, there is a need for a rapid diagnostic test to guide early targeted surfactant treatment. [18]

Professor Henrik Verder has worked with lung-maturity diagnostics on gastric aspirates obtained at birth for over 15 years. With the introduction of surfactant treatment for IRDS, Henrik Verder developed additional lung maturity tests based on gastric aspirates (GAS); for example, the microbubble stability test [19] and lamellar body counts (LBC) [20] as well as a large randomised trial using lamellar body counts to guide surfactant treatment. [21] However, a common problem with all these methods is dilution with foetal urine. Additionally, the methods are time‐consuming laboratory tests and are too slow to be used as a point‐of‐care test (POC) to guide surfactant treatment.

Professor Henrik Verder, in collaboration with chemometric scientist Agnar Hoskuldsson, developed a rapid point-of-care method for predicting IRDS by measuring the lecithin-sphingomyelin ratio (L/S) in gastric aspirate (GA). [9] The new method, which is based on mid‐red Fourier Transform Infrared spectroscopy (FTIR), [22] was shown to measure the L/S ratio at birth with a high sensitivity. [9] This rapid bedside test for surfactant components in gastric aspirate is also now available, and clinical trials of this new point-of-care test to determine surfactant need at birth are underway. [23] [9]

Lung ultrasound

Lung ultrasound, with appropriate expertise, equipment and training, may offer another alternative way of diagnosing IRDS at an earlier stage, without apparently resulting in more infants overall being treated. [10]

Prevention

Giving the baby's mother glucocorticoids speeds the production of surfactant. For very premature deliveries, a glucocorticoid is given without testing the fetal lung maturity. The American College of Obstetricians and Gynecologists (ACOG), Royal College of Medicine and other major organizations have recommended antenatal glucocorticoid treatment for women at risk for preterm delivery prior to 34 weeks of gestation. [24] Multiple courses of glucocorticoid administration, compared with a single course, do not seem to increase or decrease the risk of death or neurodevelopmental disorders of the child. [25]

In pregnancies of longer than 30 weeks, the fetal lung maturity may be tested by sampling the amount of surfactant in the amniotic fluid by amniocentesis, wherein a needle is inserted through the mother's abdomen and uterus. Several tests are available that correlate with the production of surfactant. These include the lecithin-sphingomyelin ratio ("L/S ratio"), the presence of phosphatidylglycerol (PG), and, more recently, the surfactant/albumin (S/A) ratio. For the L/S ratio, if the result is less than 2:1, the fetal lungs may be deficient in surfactant. The presence of PG usually indicates fetal lung maturity. For the S/A ratio, the result is given as milligrams of surfactant per gram of protein. A S/A ratio less than 35 indicates immature lungs, between 35 and 55 is indeterminate, and greater than 55 indicates mature surfactant production (correlating with an L/S ratio of 2.2 or greater).[ citation needed ]

Epidemiology

Infant respiratory distress syndrome (IRDS) is the leading cause of death in premature infants. [26]  Despite only 1% of all birth complications being attributed to respiratory distress syndrome, there is a significantly higher prevalence in prematurely born babies. [27] Incidence rates of IRDS in premature infants born at 30 weeks of gestational age (GA) are at 50%, and rise even higher to 93% for infants born prematurely at 28 weeks of gestational age or younger. [27] IRDS is diagnosed within hours of delivery and usually leads to morbidity and mortality in preterm infants. There are many risk factors that can potentially cause IRDS. The most common risks factors that can potentially cause IRDS include male gender, white race, late preterm delivery, maternal diabetes, perinatal hypoxia (exposure to low oxygen) and ischemia (decreased blood flow), and low birth weight. [28] Seventy percent of babies diagnosed with respiratory distress syndrome are born between 29 and 34 weeks of gestational age and are 55% more likely to be male. [27] A study conducted at the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network studied premature infants born between 22 and 37 weeks and the outcomes leading to IRDS. This study was conducted from 2002 to 2008. The incidence rate of IRDS for 24 weeks was 98%, for 34 weeks the incidence is 5%, and for 37 weeks the incidence rate was less than 1%. The results demonstrate that the incidence of IRDS increases with decreasing age at birth. [29]

According to a study from the University of Miami's Department of Pediatrics and Division of Neonatology, from the time range of 2003 to 2014, respiratory distress syndrome prevalence jumped from 170 per 1000 preterm live births to 360 per 1000 preterm live births nationwide in the United States. [30] This study population's duration under hospital care averaged 32 days in 2003, increasing by nearly a week to 38 days in 2014. [30] Additionally, this study yielded average prevalence rates of 260 cases per 1000 livebirths from the years of 2003 to 2014, [30] which coincided with the results yielded by a report from the Vermont Oxford Network in 2008 of 300 per 1000 livebirths. [31]

Treatment

Oxygen is given with a small amount of continuous positive airway pressure (CPAP), and intravenous fluids are administered to stabilize the blood sugar, blood salts and blood pressure. CPAP application to preterm neonates with respiratory distress is associated with a reduction in respiratory failure, mechanical ventilation and mortality. [32] However, CPAP is associated with an increased rate of pneumothorax compared to spontaneous breathing with or without supplemental oxygen. [32] If the baby's condition worsens, an endotracheal tube (breathing tube) is inserted into the trachea and intermittent breaths are given by a mechanical device. An exogenous preparation of pulmonary surfactant, either synthetic or extracted from animal lungs, is given through the breathing tube into the lungs. Surfactant medications can decrease the risk of death for very low-birth-weight infants who are hospitalized by 30%. [33] Such small premature infants may remain ventilated for months. A study shows that an aerosol of a perfluorocarbon such as perfluoromethyldecalin can reduce inflammation in swine model of IRDS. [34] Chronic lung disease, including bronchopulmonary dysplasia, is common in severe RDS. The etiology of BPD is problematic and may be the result of oxygen, overventilation or underventilation. The mortality rate for babies greater than 27 weeks of gestation is less than 20%.[ citation needed ]

INSURE (Intubation Surfactant Extubation) and LISA (Less Invasive Surfactant Administration) methods

Henrik Verder is the inventor and pioneer of the INSURE (Intubation Surfactant Extubation) and LISA (Less Invasive Surfactant Administration) methods combined with nasal CPAP (Continuous Positive Airway Pressure), very effective approaches to managing preterm neonates with respiratory distress. In 1989 he used this pioneering method to successfully treat the first premature infant with severe RDS. [35]

The INSURE method has been shown, through meta-analysis, to successfully decrease the use of mechanical ventilation and lower the incidence of bronchopulmonary dysplasia (BPD). [36] Since its conception in 1989, the INSURE method has been academically cited in more than 500 papers. [37] The first randomised study involving the INSURE method was published in 1994 [38] and a second randomised study in infants less than 30 weeks gestation was published by the group in 1999. [39] Based on the INSURE method, Henrik Verder has since developed a rapid bedside test that predicts IRDS at birth. [8]

Extracorporeal membrane oxygenation (ECMO)

Extracorporeal membrane oxygenation (ECMO) is a potential treatment, providing oxygenation through an apparatus that imitates the gas exchange process of the lungs. However, newborns cannot be placed on ECMO if they are under 4.5 pounds (2 kg), because they have extremely small vessels for cannulation, thus hindering adequate flow because of limitations from cannula size and subsequent higher resistance to blood flow (compare with vascular resistance). Furthermore, in infants aged less than 34 weeks of gestation, several physiologic systems are not well-developed, especially the cerebral vasculature and germinal matrix, resulting in high sensitivity to slight changes in pH, PaO2 and intracranial pressure. Subsequently, preterm infants are at unacceptably high risk for intraventricular hemorrhage (IVH) if administered ECMO at a gestational age of less than 32 weeks. [40]

Culture and society

See also

Related Research Articles

<span class="mw-page-title-main">Meconium aspiration syndrome</span> Medical condition affecting newborn infants

Meconium aspiration syndrome (MAS) also known as neonatal aspiration of meconium is a medical condition affecting newborn infants. It describes the spectrum of disorders and pathophysiology of newborns born in meconium-stained amniotic fluid (MSAF) and have meconium within their lungs. Therefore, MAS has a wide range of severity depending on what conditions and complications develop after parturition. Furthermore, the pathophysiology of MAS is multifactorial and extremely complex which is why it is the leading cause of morbidity and mortality in term infants.

<span class="mw-page-title-main">Preterm birth</span> Birth at less than a specified gestational age

Preterm birth, also known as premature birth, is the birth of a baby at fewer than 37 weeks gestational age, as opposed to full-term delivery at approximately 40 weeks. Extreme preterm is less than 28 weeks, very early preterm birth is between 28 and 32 weeks, early preterm birth occurs between 32 and 34 weeks, late preterm birth is between 34 and 36 weeks' gestation. These babies are also known as premature babies or colloquially preemies or premmies. Symptoms of preterm labor include uterine contractions which occur more often than every ten minutes and/or the leaking of fluid from the vagina before 37 weeks. Premature infants are at greater risk for cerebral palsy, delays in development, hearing problems and problems with their vision. The earlier a baby is born, the greater these risks will be.

Transient tachypnea of the newborn is a respiratory problem that can be seen in the newborn shortly after delivery. It is caused by retained fetal lung fluid due to impaired clearance mechanisms. It is the most common cause of respiratory distress in term neonates. It consists of a period of tachypnea (rapid breathing. Usually, this condition resolves over 24–72 hours. Treatment is supportive and may include supplemental oxygen and antibiotics. The chest x-ray shows hyperinflation of the lungs including prominent pulmonary vascular markings, flattening of the diaphragm, and fluid in the horizontal fissure of the right lung.

<span class="mw-page-title-main">Neonatal intensive care unit</span> Intensive care unit specializing in the care of ill or premature newborn infants

A neonatal intensive care unit (NICU), also known as an intensive care nursery (ICN), is an intensive care unit (ICU) specializing in the care of ill or premature newborn infants. The NICU is divided into several areas, including a critical care area for babies who require close monitoring and intervention, an intermediate care area for infants who are stable but still require specialized care, and a step down unit where babies who are ready to leave the hospital can receive additional care before being discharged.

<span class="mw-page-title-main">Pulmonary surfactant</span> Complex of phospholipids and proteins

Pulmonary surfactant is a surface-active complex of phospholipids and proteins formed by type II alveolar cells. The proteins and lipids that make up the surfactant have both hydrophilic and hydrophobic regions. By adsorbing to the air-water interface of alveoli, with hydrophilic head groups in the water and the hydrophobic tails facing towards the air, the main lipid component of surfactant, dipalmitoylphosphatidylcholine (DPPC), reduces surface tension.

<span class="mw-page-title-main">Pulmonary hemorrhage</span> Medical condition

Pulmonary hemorrhage is an acute bleeding from the lung, from the upper respiratory tract and the trachea, and the pulmonary alveoli. When evident clinically, the condition is usually massive. The onset of pulmonary hemorrhage is characterized by a cough productive of blood (hemoptysis) and worsening of oxygenation leading to cyanosis. Treatment should be immediate and should include tracheal suction, oxygen, positive pressure ventilation, and correction of underlying abnormalities such as disorders of coagulation. A blood transfusion may be necessary.

Antenatal steroids, also known as antenatal corticosteroids, are medications administered to pregnant women expecting a preterm birth. When administered, these steroids accelerate the maturation of the fetus' lungs, which reduces the likelihood of infant respiratory distress syndrome and infant mortality. The effectiveness of this corticosteroid treatment on humans was first demonstrated in 1972 by Sir Graham Liggins and Ross Howie, during a randomized control trial using betamethasone.

<span class="mw-page-title-main">Fetal circulation</span> Circulatory system of fetuses

In humans, the circulatory system is different before and after birth. The fetal circulation is composed of the placenta, umbilical blood vessels encapsulated by the umbilical cord, heart and systemic blood vessels. A major difference between the fetal circulation and postnatal circulation is that the lungs are not used during the fetal stage resulting in the presence of shunts to move oxygenated blood and nutrients from the placenta to the fetal tissue. At birth, the start of breathing and the severance of the umbilical cord prompt various changes that quickly transform fetal circulation into postnatal circulation.

<span class="mw-page-title-main">Respiratory disease</span> Disease of the respiratory system

Respiratory diseases, or lung diseases, are pathological conditions affecting the organs and tissues that make gas exchange difficult in air-breathing animals. They include conditions of the respiratory tract including the trachea, bronchi, bronchioles, alveoli, pleurae, pleural cavity, the nerves and muscles of respiration. Respiratory diseases range from mild and self-limiting, such as the common cold, influenza, and pharyngitis to life-threatening diseases such as bacterial pneumonia, pulmonary embolism, tuberculosis, acute asthma, lung cancer, and severe acute respiratory syndromes, such as COVID-19. Respiratory diseases can be classified in many different ways, including by the organ or tissue involved, by the type and pattern of associated signs and symptoms, or by the cause of the disease.

<span class="mw-page-title-main">Bronchopulmonary dysplasia</span> Medical condition

Bronchopulmonary dysplasia is a chronic lung disease which affects premature infants. Premature (preterm) infants who require treatment with supplemental oxygen or require long-term oxygen are at a higher risk. The alveoli that are present tend to not be mature enough to function normally. It is also more common in infants with low birth weight (LBW) and those who receive prolonged mechanical ventilation to treat respiratory distress syndrome. It results in significant morbidity and mortality. The definition of bronchopulmonary dysplasia has continued to evolve primarily due to changes in the population, such as more survivors at earlier gestational ages, and improved neonatal management including surfactant, antenatal glucocorticoid therapy, and less aggressive mechanical ventilation.

<span class="mw-page-title-main">Dipalmitoylphosphatidylcholine</span> Chemical compound

Dipalmitoylphosphatidylcholine (DPPC) is a phospholipid (and a lecithin) consisting of two C16 palmitic acid groups attached to a phosphatidylcholine head-group.

<span class="mw-page-title-main">Lecithin–sphingomyelin ratio</span> Test of fetal amniotic fluid to assess for lung immaturity

The lecithin–sphingomyelin ratio is a test of fetal amniotic fluid to assess for fetal lung immaturity. Lungs require surfactant, a soap-like substance, to lower the surface pressure of the alveoli in the lungs. This is especially important for premature babies trying to expand their lungs after birth. Surfactant is a mixture of lipids, proteins, and glycoproteins, lecithin and sphingomyelin being two of them. Lecithin makes the surfactant mixture more effective.

Poractant alfa is a pulmonary surfactant sold under the brand name Curosurf by Chiesi Farmaceutici. Poractant alfa is an extract of natural porcine lung surfactant. As with other surfactants, marked improvement on oxygenation may occur within minutes of the administration of poractant alfa. The new generic form of surfactant is Varasurf developed in PersisGen Co. and commercialized by ArnaGen Pharmad. It has fully comparable quality profile with Curosurf.

Bubble CPAP is a non-invasive ventilation strategy for newborns with infant respiratory distress syndrome (IRDS). It is one of the methods by which continuous positive airway pressure (CPAP) is delivered to a spontaneously breathing newborn to maintain lung volumes during expiration. With this method, blended and humidified oxygen is delivered via short binasal prongs or a nasal mask and pressure in the circuit is maintained by immersing the distal end of the expiratory tubing in water. The depth to which the tubing is immersed underwater determines the pressure generated in the airways of the infant. As the gas flows through the system, it "bubbles" out and prevents buildup of excess pressures.

Surfactant therapy is the medical administration of exogenous surfactant. Surfactants used in this manner are typically instilled directly into the trachea. When a baby comes out of the womb and the lungs are not developed yet, they require administration of surfactant in order to process oxygen and survive. This condition that the baby has is called newborn respiratory distress syndrome, and it is treatable. Surfactant coat the smallest parts of the lungs called the alveoli and helps for oxygen to go in and for carbon dioxide to go out. How surfactant does this is by not allowing the alveoli to collapse and to retain their inflated shape when the baby exhales.

<span class="mw-page-title-main">Henrik Verder</span>

Henrik Verder is a pediatrician and the inventor of the INSURE and LISA methods combined with nasal CPAP. In 1989 he used this pioneering method to successfully treat the first premature infant with severe RDS. Verder is a significant researcher within the field of paediatrics, with more than 50 publications and over 500 citations.

<span class="mw-page-title-main">Neonatal infection</span> Human disease

Neonatal infections are infections of the neonate (newborn) acquired during prenatal development or within the first four weeks of life. Neonatal infections may be contracted by mother to child transmission, in the birth canal during childbirth, or after birth. Neonatal infections may present soon after delivery, or take several weeks to show symptoms. Some neonatal infections such as HIV, hepatitis B, and malaria do not become apparent until much later. Signs and symptoms of infection may include respiratory distress, temperature instability, irritability, poor feeding, failure to thrive, persistent crying and skin rashes.

<span class="mw-page-title-main">Pulmonary surfactant (medication)</span>

Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies.

Christian P. Speer is a German pediatrician and Professor of Pediatrics specialized in neonatology at the Julius Maximilian University of Würzburg. Speer is known for his scientific and educational contributions in neonatal medicine.

<span class="mw-page-title-main">Henry Halliday (paediatrician)</span> British neonatologist (1945–2022)

Henry Lewis Halliday was a British-Irish peaditrician and neonatologist. In 2021, Halliday was awarded the James Spence Medal for research into neonatology, for coordinating two of the largest neonatal multicentre trials for prevention and treatment of a number of neonatal respiratory illnesses and for a breakthrough in the development of a new lung surfactant that brought relief to very small babies suffering from infant respiratory distress syndrome (RDS).

References

  1. ↑ "neonatal respiratory distress syndrome" at Dorland's Medical Dictionary
  2. ↑ Northway Jr, WH; Rosan, RC; Porter, DY (Feb 16, 1967). "Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia". The New England Journal of Medicine. 276 (7): 357–68. doi:10.1056/NEJM196702162760701. PMID   5334613.
  3. ↑ Santosham, Mathuram; Chan, Grace J.; Lee, Anne CC; Baqui, Abdullah H.; Tan, Jingwen; Black, Robert E. (2013). "Risk of Early-Onset Neonatal Infection with Maternal Infection or Colonization: A Global Systematic Review and Meta-Analysis". PLOS Medicine. 10 (8): e1001502. doi: 10.1371/journal.pmed.1001502 . ISSN   1549-1676. PMC   3747995 . PMID   23976885.
  4. ↑ Sinha, Sunil (2012). Essential neonatal medicine. Chichester, West Sussex: John Wiley & Sons. ISBN   9780470670408; Access provided by the University of Pittsburgh{{cite book}}: CS1 maint: postscript (link)
  5. ↑ Rodriguez RJ, Martin RJ, Fanaroff AA (2002). "Respiratory distress syndrome and its management". In Fanaroff, Avroy A, Martin, Richard J (eds.). Neonatal-perinatal medicine: diseases of the fetus and infant. St. Louis: Mosby. pp. 1001–1011. ISBN   978-0-323-00929-4.
  6. ↑ Edwards, Martin O.; Kotecha, Sarah J.; Kotecha, Sailesh (1 March 2013). "Respiratory Distress of the Term Newborn Infant". Paediatric Respiratory Reviews. 14 (1): 29–37. doi:10.1016/j.prrv.2012.02.002. PMID   23347658.
  7. ↑ "Infant Respiratory Distress Syndrome. IRDS information". April 2022.
  8. 1 2 Sweet, David G.; Carnielli, Virgilio P.; Greisen, Gorm; Hallman, Mikko; Klebermass-Schrehof, Katrin; Ozek, Eren; te Pas, Arjan; Plavka, Richard; Roehr, Charles C.; Saugstad, Ola D.; Simeoni, Umberto; Speer, Christian P.; Vento, Maximo; Visser, Gerry H.A.; Halliday, Henry L. (March 2023). "European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update". Neonatology. 120 (1): 3–23. doi:10.1159/000528914. ISSN   1661-7800. PMC   10064400 . PMID   36863329.
  9. 1 2 3 4 Heiring, Christian; Verder, Henrik; Schousboe, Peter; Jessen, Torben E.; Bender, Lars; Ebbesen, Finn; Dahl, Marianne; Eschen, Christian; Fenger‐Grøn, Jesper; Höskuldsson, Agnar; Matthews, Morgaine; Reinholdt, Jes; Scoutaris, Nikolaos; Smedegaard, Heidi (February 2020). "Predicting respiratory distress syndrome at birth using a fast test based on spectroscopy of gastric aspirates: 2. Clinical part". Acta Paediatrica. 109 (2): 285–290. doi:10.1111/apa.14831. ISSN   0803-5253. PMC   7004016 . PMID   31038796.
  10. 1 2 Capasso, Letizia; Pacella, Daniela; Migliaro, Fiorella; De Luca, Daniele; Raimondi, Francesco (2021-07-28). "Can lung ultrasound score accurately predict the need for surfactant replacement in preterm neonates? A systematic review and meta-analysis protocol". PLOS ONE. 16 (7): e0255332. Bibcode:2021PLoSO..1655332C. doi: 10.1371/journal.pone.0255332 . ISSN   1932-6203. PMC   8318286 . PMID   34320032.
  11. ↑ Reuter, S; Moser, C; Baack, M (October 2014). "Respiratory Distress in the Newborn". Pediatrics in Review. 35 (10): 417–429. doi:10.1542/pir.35-10-417. PMC   4533247 . PMID   25274969.
  12. ↑ "Acute Respiratory Distress Syndrome". The Lecturio Medical Concept Library. Retrieved 27 June 2021.
  13. ↑ Snyder JM, Mendelson CR (1987). "Insulin inhibits the accumulation of the major lung surfactant apoprotein in human fetal lung explants maintained in vitro". Endocrinology. 120 (4): 1250–7. doi:10.1210/endo-120-4-1250. PMID   3549256.
  14. ↑ Bahadue, Felicia L; Soll, Roger (2012-11-14). "Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome". The Cochrane Database of Systematic Reviews. 2012 (11): CD001456. doi:10.1002/14651858.CD001456.pub2. ISSN   1469-493X. PMC   7057030 . PMID   23152207.
  15. ↑ Sandri, Fabrizio; Plavka, Richard; Ancora, Gina; Simeoni, Umberto; Stranak, Zbynek; Martinelli, Stefano; Mosca, Fabio; Nona, José; Thomson, Merran; Verder, Henrik; Fabbri, Laura; Halliday, Henry; CURPAP Study Group (June 2010). "Prophylactic or early selective surfactant combined with nCPAP in very preterm infants". Pediatrics. 125 (6): e1402–1409. doi:10.1542/peds.2009-2131. ISSN   1098-4275. PMID   20439601. S2CID   19431025.
  16. ↑ Bevilacqua, G.; Parmigiani, S.; Robertson, B. (1996). "Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial". Journal of Perinatal Medicine. 24 (6): 609–620. doi:10.1515/jpme.1996.24.6.609. ISSN   0300-5577. PMID   9120744. S2CID   38291029.
  17. ↑ "Google Scholar". scholar.google.com. Retrieved 2023-05-23.
  18. ↑ Kearl, Colby R; Young, Leslie; Soll, Roger (2018-11-06). "Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome". The Cochrane Database of Systematic Reviews. 2018 (11): CD013158. doi:10.1002/14651858.CD013158. ISSN   1469-493X. PMC   6516810 .
  19. ↑ Verder, H.; Ebbesen, F.; Linderholm, B.; Robertson, B.; Eschen, C.; Arrøe, M.; Lange, A.; Grytter, C.; Bohlin, K.; Bertelsen, A.; Danish-Swedish Multicentre Study Group (June 2003). "Prediction of respiratory distress syndrome by the microbubble stability test on gastric aspirates in newborns of less than 32 weeks' gestation". Acta Paediatrica. 92 (6): 728–733. doi:10.1080/08035250310002597. ISSN   0803-5253. PMID   12856986.
  20. ↑ Verder, H.; Ebbesen, F.; Brandt, J.; Dahl, M.; Esberg, G.; Eschen, C.; Grytter, C.; Kroner, J.; Nørgaard, M.; Reinholdt, J.; Stanchev, H.; Danish-Swedish Multicenter Study Group for Surfactant Replacement (February 2011). "Lamellar body counts on gastric aspirates for prediction of respiratory distress syndrome". Acta Paediatrica. 100 (2): 175–180. doi:10.1111/j.1651-2227.2010.02010.x. ISSN   1651-2227. PMID   20840663. S2CID   24024355.
  21. ↑ Verder, Henrik; Ebbesen, Finn; Fenger-Grøn, Jesper; Henriksen, Tine Brink; Andreasson, Bengt; Bender, Lars; Bertelsen, Aksel; Björklund, Lars J.; Dahl, Marianne; Esberg, Gitte; Eschen, Christian; Høvring, Marie; Kreft, Andreas; Kroner, Jørn; Lundberg, Fredrik (2013). "Early surfactant guided by lamellar body counts on gastric aspirate in very preterm infants". Neonatology. 104 (2): 116–122. doi:10.1159/000351638. ISSN   1661-7819. PMID   23942627. S2CID   2699650.
  22. ↑ Verder, Henrik; Heiring, Christian; Clark, Howard; Sweet, David; Jessen, Torben E.; Ebbesen, Finn; Björklund, Lars J.; Andreasson, Bengt; Bender, Lars; Bertelsen, Aksel; Dahl, Marianne; Eschen, Christian; Fenger‐Grøn, Jesper; Hoffmann, Stine F.; Höskuldsson, Agnar (March 2017). "Rapid test for lung maturity, based on spectroscopy of gastric aspirate, predicted respiratory distress syndrome with high sensitivity". Acta Paediatrica. 106 (3): 430–437. doi:10.1111/apa.13683. ISSN   0803-5253. PMC   5324669 . PMID   27886403.
  23. ↑ Sweet, David G.; Carnielli, Virgilio P.; Greisen, Gorm; Hallman, Mikko; Klebermass-Schrehof, Katrin; Ozek, Eren; te Pas, Arjan; Plavka, Richard; Roehr, Charles C.; Saugstad, Ola D.; Simeoni, Umberto; Speer, Christian P.; Vento, Maximo; Visser, Gerry H.A.; Halliday, Henry L. (March 2023). "European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update". Neonatology. 120 (1): 3–23. doi:10.1159/000528914. ISSN   1661-7800. PMC   10064400 . PMID   36863329.
  24. ↑ Men-Jean Lee; Debra Guinn; Charles J Lockwood; Vanessa A Barss. "Antenatal use of glucocorticoids in women at risk for preterm delivery" . Retrieved December 16, 2013.
  25. ↑ Asztalos, EV; Murphy, KE; Willan, AR; Matthews, SG; Ohlsson, A; Saigal, S; Armson, BA; Kelly, EN; Delisle, MF; Gafni, A; Lee, SK; Sananes, R; Rovet, J; Guselle, P; Amankwah, K; Saleem, M; Sanchez, J; MACS-5 Collaborative, Group (Dec 1, 2013). "Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study: Outcomes in Children at 5 Years of Age (MACS-5)". JAMA Pediatrics. 167 (12): 1102–10. doi: 10.1001/jamapediatrics.2013.2764 . PMID   24126948.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  26. ↑ Dyer, Janet (2019). "Neonatal Respiratory Distress Syndrome: Tackling A Worldwide Problem". Pharmacy and Therapeutics. 44 (1): 12–14. ISSN   1052-1372. PMC   6336202 . PMID   30675087.
  27. 1 2 3 Stoll, B. J.; Hansen, N. I.; Bell, E. F.; Shankaran, S.; Laptook, A. R.; Walsh, M. C.; Hale, E. C.; Newman, N. S.; Schibler, K.; Carlo, W. A.; Kennedy, K. A. (2010-09-01). "Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network". Pediatrics. 126 (3): 443–456. doi:10.1542/peds.2009-2959. ISSN   0031-4005. PMC   2982806 . PMID   20732945.
  28. ↑ Li, Yan; Wang, Weijing; Zhang, Dongfeng (2019). "Maternal diabetes mellitus and risk of neonatal respiratory distress syndrome: a meta-analysis". Acta Diabetologica. 56 (7): 729–740. doi:10.1007/s00592-019-01327-4. ISSN   1432-5233. PMID   30955125. S2CID   102349516.
  29. ↑ Smith, P. Brian; Ambalavanan, Namasivayam; Li, Lei; Cotten, C. Michael; Laughon, Matthew; Walsh, Michele C.; Das, Abhik; Bell, Edward F.; Carlo, Waldemar A.; Stoll, Barbara J.; Shankaran, Seetha (2012). "Approach to infants born at 22 to 24 weeks' gestation: relationship to outcomes of more-mature infants". Pediatrics. 129 (6): e1508–1516. doi:10.1542/peds.2011-2216. ISSN   1098-4275. PMC   3362905 . PMID   22641761.
  30. 1 2 3 Donda, Keyur; Vijayakanthi, Nandini; Dapaah‐Siakwan, Fredrick; Bhatt, Parth; Rastogi, Deepa; Rastogi, Shantanu (2019-01-20). "Trends in epidemiology and outcomes of respiratory distress syndrome in the United States". Pediatric Pulmonology. 54 (4): 405–414. doi:10.1002/ppul.24241. ISSN   8755-6863. PMID   30663263. S2CID   58665454.
  31. ↑ Horbar, Jeffrey D.; Soll, Roger F.; Edwards, William H. (2010). "The Vermont Oxford Network: A Community of Practice". Clinics in Perinatology. 37 (1): 29–47. doi:10.1016/j.clp.2010.01.003. ISSN   0095-5108. PMID   20363446.
  32. 1 2 Ho, Jacqueline J; Subramaniam, Prema; Davis, Peter G (2020-10-15). "Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants". Cochrane Database of Systematic Reviews. 2020 (10): CD002271. doi:10.1002/14651858.cd002271.pub3. ISSN   1465-1858. PMC   8094155 . PMID   33058208.
  33. ↑ Schwartz, RM; Luby, AM; Scanlon, JW; Kellogg, RJ (May 26, 1994). "Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g". The New England Journal of Medicine. 330 (21): 1476–80. doi: 10.1056/NEJM199405263302102 . PMID   8164699.
  34. ↑ von der Hardt, K; Schoof, E; Kandler, MA; Dötsch, J; Rascher, W (February 2002). "Aerosolized perfluorocarbon suppresses early pulmonary inflammatory response in a surfactant-depleted piglet model". Pediatric Research. 51 (2): 177–82. doi: 10.1203/00006450-200202000-00009 . PMID   11809911.
  35. ↑ Henrik, Verder (23 May 2023). "Research Gate".
  36. ↑ Stevens, TP; Blennow, M; Soll, RF (2004). Stevens, Timothy (ed.). "Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome". The Cochrane Database of Systematic Reviews (3): CD003063. doi:10.1002/14651858.CD003063.pub2. PMID   15266470.
  37. ↑ "Henrik Verder research profile". www.Researchgate.net. Retrieved 15 July 2014.
  38. ↑ Verder, H; Robertson, B; Greisen, G; Ebbesen, F; Albertsen, P; Lundstrøm, K; Jacobsen, T (Oct 20, 1994). "Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group". The New England Journal of Medicine. 331 (16): 1051–5. doi: 10.1056/nejm199410203311603 . PMID   8090164.
  39. ↑ Verder, H; Albertsen, P; Ebbesen, F; Greisen, G; Robertson, B; Bertelsen, A; Agertoft, L; Djernes, B; Nathan, E; Reinholdt, J (Feb 1999). "Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation". Pediatrics. 103 (2): E24. doi:10.1542/peds.103.2.e24. PMID   9925870.
  40. ↑ Jobe, Alan H. (August 2004). "Post-conceptional age and IVH in ECMO patients". The Journal of Pediatrics. 145 (2): A2. doi:10.1016/j.jpeds.2004.07.010.
  41. ↑ Altman, Lawrence (2013-07-29). "A Kennedy Baby's Life and Death". The New York Times. The New York Times. Retrieved 6 June 2015.
  42. ↑ Dunne, Dominick (2008-04-08). "Justice". Vanity Fair. Retrieved 31 October 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.